Fiscal Year Ending March 2026, Q3 Financial Summary [Japanese GAAP] (Consolidated)

Overview of Business Performance

For the third quarter of the fiscal year ending March 2026, consolidated results were net sales of ¥92,456 million (3.6% increase YoY), operating income of ¥4,609 million (47.9% increase YoY), ordinary income of ¥5,097 million (35.8% increase YoY), and net income attributable to owners of the parent of ¥4,119 million (68.9% increase YoY). Growth in new drug sales and the recording of special gains from the sale of investment securities contributed to the increase in profits. Domestic sales of new pharmaceuticals were ¥65,042 million (3.4% increase YoY), overseas new pharmaceuticals were ¥580 million (12.1% increase YoY), and generic drugs sales were ¥26,833 million (3.7% increase YoY).

Overview of Financial Position and Future Outlook

Total assets stood at ¥194,266 million, net assets at ¥138,869 million, and equity ratio improved to 71.5% compared to the previous fiscal year-end. Research and development expenses were ¥7,534 million (6.5% decrease YoY), with progress seen in key development pipelines. The full-year earnings forecast for the fiscal year ending March 2026 anticipates net sales of ¥127,000 million (2.4% decrease YoY), operating income of ¥6,100 million (51.5% decrease YoY), and net income attributable to owners of the parent of ¥4,800 million (47.2% decrease YoY), with no recent revisions to this guidance.